As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -19 -19 |
20%
20%
|
EBIT (Operating Income) EBIT | -19 -19 |
19%
19%
|
Net Profit | -67 -67 |
23%
23%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.
Head office | United States |
CEO | David Weinstein |
Employees | 25 |
Founded | 2011 |
Website | renovarobio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.